<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>An Inconvenient Woman &#187; The Lancet</title>
	<atom:link href="http://iconicwoman.com/tags/the-lancet/feed/" rel="self" type="application/rss+xml" />
	<link>http://iconicwoman.com</link>
	<description>Don’t Get Angry, Get Active!</description>
	<lastBuildDate>Thu, 19 Jan 2012 09:10:07 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Lancet Study Indicates Cervarix HPV Vaccine Effective Against The Five Most Common Cervical Cancer-Causing Viruses</title>
		<link>http://iconicwoman.com/hpv-vaccine/lancet-study-indicates-cervarix-hpv-vaccine-effective-against-the-five-most-common-cervical-cancer-causing-viruses/</link>
		<comments>http://iconicwoman.com/hpv-vaccine/lancet-study-indicates-cervarix-hpv-vaccine-effective-against-the-five-most-common-cervical-cancer-causing-viruses/#comments</comments>
		<pubDate>Tue, 07 Jul 2009 20:33:57 +0000</pubDate>
		<dc:creator>H. Sandra Chevalier-Batik</dc:creator>
				<category><![CDATA[HPV Vaccine]]></category>
		<category><![CDATA[Cervical Cancer]]></category>
		<category><![CDATA[cervical cancer vaccine clinical trials]]></category>
		<category><![CDATA[GlaxoSmithKline Cervarix]]></category>
		<category><![CDATA[HPV Vaccines]]></category>
		<category><![CDATA[HPV-Associated Cervical Cancer]]></category>
		<category><![CDATA[The Lancet]]></category>

		<guid isPermaLink="false">http://iconicwoman.com/?p=1371</guid>
		<description><![CDATA[A study, published in Tuesday's issue of The Lancet, said that as well as protecting against the two most common virus types, the GlaxoSmithKline Plc's Cervarix vaccine also provides protection against the next three most common cancer-causing virus types.  GlaxoSmithKline Plc's is Europe's biggest drug company.]]></description>
			<content:encoded><![CDATA[<h2>GSK says Cervarix effective against more viruses</h2>
<div class="timestampHeader">Earlier this week Reuters reported the results of a Cervarix study published in a recent issue of The Lancet that indicated that the Glaxo HPV vaccine protects against the five most common cervical cancer-causing viruses. Below is a excerpt of that story and a link back to the full article published by Reuters.</div>
<div><script src="http://static.reuters.com/resources/js/articlePartnerAttribution.js" type="text/javascript"></script></div>
<p><script type="text/javascript"><!--
var csvSymbolIds = "";
var quoteLink = "true";
// --></script></p>
<div class="inlineRelatedContent"><span id="trackingEnabledModule"> <script type="text/javascript"><!--
addImpression("3098094_Related Video");
// --></script> <script type="text/javascript"><!--
removeImpression();
// --></script> </span> <span id="trackingEnabledModule"> <script type="text/javascript"><!--
addImpression("3098095_Related News");
// --></script> <script type="text/javascript"><!--
removeImpression();
// --></script> </span></p>
<div class="linebreak"><!-- No Data Found, skipping --></div>
<div>
<div class="NONE" style="margin-bottom: 0px;"><!-- BEGIN:: Shared Module id=86284 --> <!-- END:: Shared Module id=86284 --></div>
</div>
</div>
<p>LONDON (Reuters) &#8211; GlaxoSmithKline Plc&#8217;s Cervarix is the first product of its kind to show it protects against the five most common cervical cancer-causing viruses, Europe&#8217;s biggest drug company said in a statement on Tuesday.</p>
<p>A study, published in Tuesday&#8217;s issue of The Lancet, said that as well as protecting against the two most common virus types, the vaccine also provides protection against the next three most common cancer-causing virus types.</p>
<p>Glaxo said the additional efficacy could translate into approximately 11 to 16 percent extra protection against cervical cancer over and above the protection afforded by efficacy against the two most common types alone.</p>
<p>&#8220;This is really good news for primary prevention of cervical cancer as it indicates the vaccine could offer women additional protection &#8230; beyond what had at first been anticipated,&#8221; said Thomas Breuer, head of global clinical R&amp;D at GSK Biologicals.  <a href="http://iconicwoman.com/wp-content/plugins/wordpress-feed-statistics/feed-statistics.php?url=aHR0cDovL3d3dy5yZXV0ZXJzLmNvbS9hcnRpY2xlL2hlYWx0aE5ld3MvaWRVU1RSRTU2NTZLWTIwMDkwNzA2" target=\"_blank\">Click here for the full article published by Reuters</a>.</p>
<p>&copy;2012 <a href="http://iconicwoman.com/wp-content/plugins/wordpress-feed-statistics/feed-statistics.php?url=aHR0cDovL2ljb25pY3dvbWFuLmNvbQ==">An Inconvenient Woman</a>. All Rights Reserved.</p>. <img src="http://iconicwoman.com/wp-content/plugins/wordpress-feed-statistics/feed-statistics.php?view=1&post_id=1371" width="1" height="1" style="display: none;" />]]></content:encoded>
			<wfw:commentRss>http://iconicwoman.com/hpv-vaccine/lancet-study-indicates-cervarix-hpv-vaccine-effective-against-the-five-most-common-cervical-cancer-causing-viruses/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
<!-- WP Super Cache is installed but broken. The path to wp-cache-phase1.php in wp-content/advanced-cache.php must be fixed! -->
